Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung:A case report and review of literature

作     者：Jing-Yi Wu Kai Kang Jing Yi Bin Yang 

作者机构：Department of Thoracic OncologyHubei Cancer HospitalTongji Medical CollegeHuazhong University of Science and TechonologyWuhan 430000Hubei ProvinceChina Department of Thoracic Oncology SurgeryHubei Cancer HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430070Hubei ProvinceChina 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2022年第10卷第18期

页      面：6110-6118页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Pembrolizumab Stevens-Johnson syndrome Advanced squamous cell carcinoma Lung Immune-related adverse events Case report 

摘      要：BACKGROUND For advanced lung squamous cell carcinoma,immune checkpoint inhibitors(ICIs)have been regarded as one of the optimal *** immune-related adverse events(ir AEs)are common in ICI treatment,cutaneous toxicities are among the most common ir *** immune-related skin toxicity grades are low,and the prognosis is ***,Stevens-Johnson syndrome(SJS)is a rare but extremely severe cutaneous adverse drug reaction with high *** SUMMARY We report a rare case of SJS induced by *** case involved a 68-year-old female who was diagnosed with advanced squamous cell carcinoma of the *** appeared after one cycle of immunotherapy combined with *** treatment with prednisone hormone symptoms,antiinfection,gamma globulin,and antipruritic agents,the skin toxicity of the patients gradually decreased and eventually *** the antitumor treatment was stopped due to serious adverse reactions,the tumor of the patient remained stable for nearly half a year after one cycle of immune therapy combined with chemotherapy,which also corroborates the delayed effect of *** We believe our report can provide some references for the treatment of SJS and the treatment of immune-related adverse reactions.